DNAJC10 correlates with tumor immune characteristics and predicts the prognosis of glioma patients
Background: The role of DNAJC10 in cancers have been reported but its function in glioma is not clear. We reveal the prognostic role and underlying functions of DNAJC10 in glioma in this study. Methods: Reverse Transcription and Quantitative Polymerase Chain Reaction (RT-qPCR) was used to quantify the relative DNAJC10 mRNA expression of clinical samples. Protein expressions of clinical samples were tested by Western blot. The overall survival (OS) of glioma patients with different DNAJC10 expression was compared by Kaplan-Meier method (two-sided log-rank test). Single-sample gene set enrichment analysis (ssGSEA) was used to estimate the immune cell infiltrations and immune-related function levels. The independent prognostic role of DNAJC10 was determined by univariate and multivariate Cox regression analysis. The DNAJC10-based nomogram model was established using multivariate Cox regression by R package “rms”. Results: Higher DNAJC10 is observed in gliomas and it’s upregulated in higher grade, IDH-wild, 1p/19q non-codeletion, MGMT unmethylated gliomas. Gliomas with higher DNAJC10 expression present poorer prognosis compared with low-DNAJC10 gliomas. The predictive accuracy of 1/3/5-OS of DNAJC10 is found stable and robust using time-dependent ROC model. Enrichment analysis recognized that T-cell activation and T-cell receptor signaling were enriched in higher DNAJC10 gliomas. Immune/stromal cell infiltrations, tumor mutation burden (TMB), copy Number Alteration (CNA) burden, and immune check-point genes were also positively correlated with DNAJC10 expression in gliomas. DNAJ10-based nomogram model was established and showed strong prognosis-predictive ability. Conclusion: Higher DNAJC10 expression correlates with poor prognosis of glioma and it was a potential prognostic biomarker for glioma.